Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22


19177 items
4:00 PM, Jan 17, 2018  |  BioCentury | Emerging Company Profile

Computing brain entry

1st Biotherapeutics Inc. aims to develop a pipeline of first- or best-in-class molecules for CNS diseases by using computational tools to achieve better blood-brain barrier penetration and PK properties than marketed drugs against the same...
7:11 PM, Jan 12, 2018  |  BioCentury | Finance

JPM jolt

Fifteen biotechs that presented at the 2018 J.P. Morgan Healthcare Conference posted gains of at least 15%, with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) leading the risers after announcing that its board rejected two unsolicited acquisition proposals...
5:27 PM, Jan 12, 2018  |  BioCentury | Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
4:43 PM, Jan 12, 2018  |  BioCentury | Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
4:19 PM, Jan 12, 2018  |  BioCentury | Finance

Soft Impact

Underwhelmed by the proposed acquisition of Impact Biomedicines Inc. by Celgene Corp. (NASDAQ:CELG), buysiders hope to see the big biotech further expand its revenue base beyond Revlimid lenalidomide through additional deals in the near term....
4:02 PM, Jan 12, 2018  |  BioCentury | Finance

Assessing Ablynx

While a group of investors in Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) don’t agree on what is fair value for the Belgian biotech, they do think a $2.8 billion offer from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) undervalues...
1:25 PM, Jan 11, 2018  |  BioCentury | Strategy

Leading by example

A third-party cost-effectiveness analysis of CAR T therapies Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel suggests that Novartis AG may need to price Kymriah differently for its second indication. Fortunately, the pharma is already discussing such...
2:49 PM, Jan 10, 2018  |  BioCentury | Politics, Policy & Law

Not so bad

The decision by Congress to cut the Orphan Drug tax credit in half in the tax reform law is unlikely to substantially reduce investment in medicines for rare diseases, according to drug developers and public...
3:25 PM, Jan 09, 2018  |  BioCentury | Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
5:06 PM, Jan 05, 2018  |  BioCentury | Strategy

CAR dealing

Johnson & Johnson’s deal with Legend Biotech will net the pharma both an anti-BCMA CAR T therapy and a partner to help shape its cell therapy strategy. J&J chose the Chinese company’s LCAR-B38M as its first...